{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:20Z","timestamp":1789646600674,"version":"4.0.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":259,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hemorrhagic cystitis (HC) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), especially in cases with haploidentical donors. Our study aimed to determine the incidence and analyze the risk factors associated with HC in patients undergoing allogeneic HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods<\/jats:title>\n                    <jats:p>This retrospective, cross\u2010sectional study analyzed data from 343 patients who underwent allogeneic HSCT between January 2012 and June 2025 at our institution. The research variables included clinical characteristics, conditioning regimens, BK virus (BKV) status, and transplant outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall incidence of HC was 18.4% (63 out of 343 patients), with severe cases (Grades 3\u20104) comprising 9.4%. The median onset was 33\u2009days posttransplantation, with a median duration of 40\u2009days. BKV was detected in the urine of 19.9% of the patients, among whom 15.2% exhibited high viral loads. Multivariate Cox regression analysis identified three independent risk factors: malignant disease (hazard ratio [HR]\u2009=\u20094.212;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046), posttransplant severe infection (HR\u2009=\u20091.793;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033), and the use of posttransplant cyclophosphamide (PTcy) (HR\u2009=\u20093.404;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Regarding prognosis, the presence of HC did not significantly affect the 5\u2010year overall survival (OS) probability (67.1% vs. 65.7% in the non\u2010HC group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.921). However, patients with Grades 3\u20104 HC exhibited a significantly lower 5\u2010year OS than those with Grades 1\u20102 (49.6% versus 86.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HC is a prevalent complication of allogeneic HSCT, often presenting late and closely associated with malignancies, severe infections, and PTcy protocols. The severity of HC is a crucial determinant of survival outcomes, necessitating proactive preventive strategies and timely interventions to enhance the patient\u2019s prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/ah\/4650693","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:30:01Z","timestamp":1789644601000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhagic Cystitis in Patients Who Underwent Allogeneic Stem Cell Transplantation (2012\u20132025): A Single\u2010Center Experience"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1698-6361","authenticated-orcid":false,"given":"Khanh Ba","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Thi Thanh","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4884-0522","authenticated-orcid":false,"given":"Thanh Ha","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412y.0000000010"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2018.03.018"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936121991377"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2014.420"},{"key":"e_1_2_11_5_2","article-title":"ECIL Guidelines for the Prevention, Diagnosis and Treatment of BK Polyomavirus-Associated Haemorrhagic Cystitis in Haematopoietic Stem Cell Transplant Recipients","volume":"73","author":"Cesaro S.","year":"2018","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"e_1_2_11_6_2","first-page":"217","article-title":"Treatment Protocols for BK Virus Associated Hemorrhagic Cystitis After Hematopoietic Stem Cell Transplantation","volume":"10","author":"Mohammadi N. M.","year":"2020","journal-title":"American Journal of Blood Research"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12455"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03930-w"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2021.0104"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001648"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.81"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0007"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182333"},{"key":"e_1_2_11_14_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda A.","year":"2024"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.05.002"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.013"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.441"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.012"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05121-9"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01364-0"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piae093.057"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/4650693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ah\/4650693","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/4650693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:30:03Z","timestamp":1789644603000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ah\/4650693"}},"subtitle":[],"editor":[{"given":"Kalyani","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/ah\/4650693"],"URL":"https:\/\/doi.org\/10.1155\/ah\/4650693","archive":["Portico"],"relation":{},"ISSN":["1687-9104","1687-9112"],"issn-type":[{"value":"1687-9104","type":"print"},{"value":"1687-9112","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"4650693"}}